How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,400 results for

Six Item Cognitive Impairment Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1321. Clinical practice guidelines for the management of early breast cancer

. The guidelines were based on a review of the available evidence about the management of breast cancer and were developed by a multidisciplinary team. In the six years since their launch, the guidelines were very well received by clinicians and were viewed by women as an important resource in understanding their treatment choices. Commencing in December 1998, the iSource National Breast Cancer Centre undertook a revision of these guidelines. Ongoing review is vital if the guidelines are to remain a good (...) cent of all breast cancer. 56 These mutations can be transmitted through either the maternal or paternal lines. It is now technically possible to determine whether a person has inherited some BRCA1 or BRCA2 mutations. With current technology, it is not possible to detect every mutation and only a few Australian laboratories can conduct this specialised testing. Genetic testing raises complex medical and ethical issues, and should only be offered with pre- and post-test counselling in conjunction

2001 Cancer Australia

1322. APA Guidelines on Multicultural Education, Training, Research, Practice and Organizational Change for Psychologists

/Hispanic/Latinx, Asian/Asian American/Pacific Islander, Black/African American/Black American, and White/White American (Trimble & Dickson, 2005). Psychologists strive to understand the need to become acquainted with aspects of identity, as well as which aspects of identity are especially relevant to the presenting problem or issue. Identity is a construct that has been central to theories of psychological development. Identity reflects both individual and collective features of emotional and cognitive

2002 American Psychological Association

1323. Enhancing Healthy Adolescent Development

toward changing social, environmental and economic conditions so as to alleviate their impact on public and individual health. The World Health Organization (1998) noted that participation is essential to sustain health promotion action, and identified six key strategies for health promotion: 1) building healthy public policy; 2) creating supportive environments; 3) strengthening community action; 4) developing personal skills; 5) reorienting health services; and 6) moving into the future. Enhancing (...) Development Adolescence is a time in one’s life when significant biological, cognitive, emotional, social and ethical development occurs. Mastery of a series of interdependent developmental tasks is central to the concept of adolescence as a transition from childhood to adulthood. Developmental Tasks of Adolescence (Lerner & Galambos, 1998) 1. Achieving increased independence 2. Adjusting to sexual maturation 3. Establishing cooperative relationships with peers 4. Preparing for meaningful vocation 5

2002 Registered Nurses' Association of Ontario

1324. Risk Assessment and Prevention of Pressure Ulcers

and working towards an evidence-based practice culture. Now comes the true test in this phenomenal journey: will nurses utilize the guidelines in their day-to-day practice? Successful uptake of these NBPG requires a concerted effort of four groups: nurses themselves, other healthcare colleagues, nurse educators in academic and practice settings, and employers. After lodging these guidelines into their minds and hearts, knowledgeable and skillful nurses and nursing students need healthy and supportive work (...) of Canada, London, Ontario Dr. Marisa Zorzitto Regional Geriatric Service, West Park Healthcare Centre, Toronto, Ontario RNAO also wishes to acknowledge the following organizations in Ottawa, Ontario, for their role in pilot testing the original guideline: SCO Health Services The Rehabilitation Centre of the Royal Ottawa Health Care Group St Patrick’s Nursing Home Perley Rideau Centre of the Royal Ottawa Health Care Group Hôpital Montfort Saint Elizabeth Health Care VHA Home Healthcare RNAO sincerely

2002 Registered Nurses' Association of Ontario

1325. Promoting Continence Using Prompted Voiding

; ¦ Individualized toileting; ¦ The impact of cognitive impairment on ability to be continent and strategies to manage aggressive behaviours; ¦ Relation of bowel hygiene care to healthy bladder functioning; and ¦ Use of a voiding record with individualized toileting. 13.0 Nurses should be knowledgeable about community resources for IV professional development, referral and ongoing assistance. Organization & Policy 14.0 Successful implementation of prompted voiding requires: IV Recommendations ¦ Management (...) incontinence is the involuntary passage of urine occurring soon after a strong sense of urgency to void. Stress incontinence is a loss of urine with coughing and or sneezing resulting in increased abdominal pressure. Mixed incontinence is urine loss having features of both stress and urge. Functional incontinence is urinary leakage associated with inability to access the toilet because of impairment of cognitive and/or physical functioning or an environmental barrier. Overflow incontinence

2002 Registered Nurses' Association of Ontario

1326. Lumbar Stenosis Outcomes Research II

scan demonstrating at least one level of lumbar spinal stenosis within 1 year Duration of symptoms > 3 months Age > 50 years; male or female Exclusion Criteria: Past or present existence of a movement disorder, e.g., Parkinsonism, or an neurologic disease that might affect the ability to ambulate (e.g., signs/symptoms of cauda equina compression) Cognitive impairment preventing full understanding or participation in the study Peripheral vascular disease Moderate to severe arthritis of the knee (...) of drug or alcohol dependence Serious intercurrent illness Hypersensitivity to oxymorphone hydrochloride Hypersensitivity to propoxyphene or acetaminophen Severe bronchial asthma or hypercarbia, morphine analogs such as codeine, or any of the other ingredients of Opana Suspicion of paralytic ileus Moderate or severe hepatic impairment Major conduction abnormality on ECG or cardiac (Bruce protocol) stress test within the past year. Ongoing treatment with a long-acting opioid or regularly-scheduled use

2008 Clinical Trials

1327. Implementing Sleep Interventions for Older Veterans

that sleep problems are associated with depressive symptoms and other impairments in quality of life in older people, and that nonpharmacological and behavioral interventions can improve sleep in a variety of settings. Objectives: We propose to test two methods of providing behavioral sleep interventions for treating insomnia in older veterans. The long-term objective of this work is to identify ways to improve access to behavioral sleep interventions for older veterans, in order to improve their well (...) ), and have transportation to VA GLAHS to attend the intervention/control programs. Exclusion Criteria: Significant cognitive impairment (MMSE score <24) and have evidence of sleep apnea (by questionnaire and/or sleep monitoring). Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov

2008 Clinical Trials

1328. Supplementing Hearing Aids With Computerized Auditory Training

four-weeks of placebo auditory training, consisting of directed listening (DL) to books-on-tape. The participants in each group will attend four test sessions. During Session 1 the informed consent process will be completed, baseline assessments will be made to ensure that the participants meet the study inclusion criteria (page 52), testing of predictor variables (page 57-58) will be completed, and all hearing aids will be assessed for correct functionality (page 53). The participants (...) then will be assigned randomly to a study group. Session 2 will occur four weeks after Session 1. During Session 2, baseline performance on the outcome measures will be assessed (page 54-57), as will performance on the predictor variables. Following testing, the participants in Groups 1 and 3 will receive training in the use of the AT or DL programs. Session 3 will occur at the end of the 4-week experimental training period. During Session 3 all participants will be retested on the outcome measures to assess short

2008 Clinical Trials

1329. Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

, 2017 Sponsor: Icahn School of Medicine at Mount Sinai Collaborators: National Institute of Mental Health (NIMH) Massachusetts General Hospital Information provided by (Responsible Party): Dan V. Iosifescu, Icahn School of Medicine at Mount Sinai Study Details Study Description Go to Brief Summary: This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same (...) with bipolar disorder who are in remission can also reduce their neurocognitive deficits and improve the quality of their life. The study will also examine the safety of the drug for use in the obsessive-compulsive disorder population. Participation in this study will last about 18 weeks and will involve six study visits. Each of the first two visits will include 2 hours of clinical, physical, and self-report tests, the first for screening and the second to establish physical and mental health baseline

2008 Clinical Trials

1330. Treatment of Mild to Moderate Depression Symptoms in Patients With Spinal Cord Injury

six months prior to enrollment. Neurological impairment ASIA Grades A-D. Mild to moderate depressive symptoms. English speaker Age 18 years or older Able to communicate with study personnel Exclusion Criteria: No neurological impairment due to SCI. Presence of cognitive deficits precluding and giving informed consent and completion of survey based assessment tools. Psychiatric contraindications (suicidal ideation, history of suicidal attempts, alcohol and drug dependency, other psychiatric (...) Sponsor: University of Michigan Collaborator: U.S. Department of Education Information provided by (Responsible Party): Denise Tate, University of Michigan Study Details Study Description Go to Brief Summary: This study was initially designed to test the efficacy of Venlafaxine HCl in reducing incidence of the onset of major depression after a new spinal cord injury (SCI). After several protocol modifications, the purpose of the study is to test the effectiveness of a sub-therapeutic dose

2008 Clinical Trials

1331. Treatments for Psychogenic Nonepileptic Seizures (NES)

and weeks 2, 6, 10 (total time frame of 12 weeks) ] The FAD is a 60 item self-report questionnaire designed to assess the six dimensions of the McMaster Model of Family Functioning, as well as overall level of family functioning through the General Functioning Scale. Each question is scored on a "1" to "4" scale, with a higher mean score relating to a worse general functioning. Longitudinal Interval Follow-Up Evaluation Range of Impaired Functioning Tool (LIFE-RIFT) [ Time Frame: Baseline and weeks 2, 6 (...) outcome. Dissociative Experiences Scale (DES) [ Time Frame: Baseline and weeks 2, 6, 10 (total time frame of 12 weeks) ] The DES is a 28 item self-report questionnaire designed to quantify dissociative experiences which identifies disturbances in memory, identity, cognition, derealization, depersonalization, absorption and imagination. A visual analogue scale is used ranging from 0% ("This never happens to you") to 100% ("This always happens to you"). The score is divided by 28 items to yield a range

2005 Clinical Trials

1332. Patient-Centered Medication Adherence Intervention for Schizophrenia

Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: medical chart diagnosis of schizophrenia or schizoaffective disorder; currently prescribed outpatient antipsychotic medication (oral or depot); patient must have adequate capacity to provide informed consent, understand the nature of the study, and sign an informed consent document. Exclusion Criteria: - significant cognitive impairment as indicated by a score > 10 on the Blessed Orientation-Memory-Concentration (BOMC (...) BFMs and compatible with CPRS. The long-term objective of this proposed research is to improve antipsychotic medication adherence and clinical outcomes for patients with schizophrenia using a cost-effective medication adherence intervention. The short-term objectives are to refine and test a patient-centered medication adherence intervention for VA patients with schizophrenia and specifically to: 1. Enhance the feasibility and acceptability of the BFM intervention by reducing the burden on patients

2005 Clinical Trials

1333. DAPHNE (Duodopa in Advanced Parkinson's: Health Outcomes & Net Economic Impact)

. Six conceptual dimensions were defined; four subjectively-reported: 'walking', 'satisfied', 'dyskinesia', and 'off' and two objectively-measured: 'tapping' and 'spiral'. Each of the items was assessed in the morning and during the day. Drawing impairment was assessed as a spiral score, where the participant is asked to draw a spiral. 1 is worst score, 10 is best. Other Outcome Measures: UPDRS Total Score up to Month 36 [ Time Frame: Months 0, 3, 6, 9, 18, 24, 30, 36, endpoint (last non-missing (...) for the participant) ] The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible, which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms

2005 Clinical Trials

1334. Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke

is to first demonstrate the effectiveness of these two types of surface stimulation on decreasing motor impairment and activity limitation; the study also seeks to assess the effect of adding cognitive input to NMES to reduce motor impairment and activity limitation. Study subjects will be acute stroke survivors. They will participate for a total of eight months, beginning within the first six months after their stroke. Subjects will be randomly assigned to one of three treatment groups and will receive (...) Measures Go to Primary Outcome Measures : Fugl-Meyer Motor Assessment (FMA) - Motor Impairment Measure [ Time Frame: FMA will be administered on 6 occasions: at baseline, mid-treatment, end of treatment, and follow-up at 1-,3- and 6-months post-treatment. ] The FMA battery measures six dimensions of post-stroke impairment including upper and lower limb motor impairment, range of motion, pain, reflexes, and sensation. , "Each item (33 total) is graded on a 3-point ordinal scale (0, cannot perform; 1

2005 Clinical Trials

1335. Improving Chronic Pain Treatment in Primary Care

to chronic pain treatment. Condition or disease Intervention/treatment Phase Pain Chronic Disease Depression Behavioral: Assistance with Pain treatment Not Applicable Detailed Description: Background: Chronic pain is very common, and associated with substantial impairment and increased healthcare utilization. Implementation of treatment guidelines has been problematic, and chronic pain remains undertreated. Because of the prevalence of chronic pain among veterans, the VHA created a National Pain (...) Management Strategy and adopted pain as the "5th vital sign." Objectives: Our primary objective was to determine to what extent a collaborative intervention improves chronic pain-related outcomes (pain-related function, pain severity and depression severity) in a VA primary care setting over six and 12 months. We also investigated to what extent the intervention affected 1) treatment of comorbid depression, 2) adherence of providers to guidelines for chronic pain, 3) patient and provider satisfaction

2005 Clinical Trials

1336. Continuous Positive Airway Pressure to Improve Milder Obstructive Sleep Apnea

) Recent or recurring history of substance abuse leading to tolerance or dependence Pregnant; women must either be postmenopausal or confirmed not pregnant by a urine pregnancy test Unable to perform study tests, e.g., inability to communicate verbally; inability to write and read in English; less than a 5th grade reading level (evaluated using Flesch-Kincaid assessment); visual impairment; hearing impairment; cognitive impairment (e.g., previous head injury); or upper extremity motor deficit (e.g (...) for leak. Device: Sham CPAP device - CPAP device with pressure delivered <1 cm H20 Sham CPAP device used at night Outcome Measures Go to Primary Outcome Measures : Change in the Score of the Functional Outcomes of Sleep Questionnaire at Baseline and Week 8 Treatment [ Time Frame: 8 weeks ] The primary endpoint is change after 8 weeks of treatment from baseline value (controlling for baseline value) in the 30-item Functional Outcomes of Sleep Questionnaire (FOSQ) that will be used to test the primary

2004 Clinical Trials

1337. Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

: Progesterone antagonist Outcome Measures Go to Primary Outcome Measures : Change in Premenstrual Tension Syndrome Scale (PMTS) Factors Associated With Premenstrual Symptoms. [ Time Frame: Every 2 weeks for 3 months ] The PMTS observer scales assess symptoms in ten different domains including irritability-hostility; tension; efficiency; dysphoria; moodiness; motor coordination; mental-cognitive functioning; eating habits; sexual drive and activity; physical symptoms and social impairment. They have been (...) premenstrual syndrome (PMDD). Previous studies have shown that the hormones estrogen and progesterone regulate mood in women with MRMD. This study will use various treatment regimens with birth control pills and placebo (sugar pill) to clarify the relationships among estrogen and progesterone, the menstrual cycle, and mood. Healthy women between 18 and 45 years of age who menstruate may be eligible for this 15-week study. Candidates are screened with a physical examination, blood and urine tests

2004 Clinical Trials

1338. R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

of participants aged 6-18 years completed the Impact of Pediatric Illness (IPI) Scale about their child prior to the start of cycles 1, 4, 7, and 10 and then after every 6 cycles. The IPI Scale assesses QOL in 4 domains: adaptive behavior, emotional functioning, medical/physical status, and cognitive functioning. Responses to the 43 items are made on a 5-point Likert scale (1-5) ranging from "not al all" to "a lot". Higher mean scores indicate better QOL. Parent total scores for participants on placebo were (...) Power of Attorney (DPA): All patients 18 years of age will be offered the opportunity to assign DPA so that another person can make decisions about their medical care if they become incapacitated or cognitively impaired. Ability to undergo MRI examinations. EXCLUSION CRITERIA: Pregnant or breast feeding females are excluded, because the toxic effects and pharmacology of R115777 in the fetus and newborn are unknown. Clinically significant unrelated systemic illness (serious infections or significant

2006 Clinical Trials

1339. Citicoline for Bipolar 1 Disorder and Cocaine Dependence

identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects. Drug: Placebo Inactive ingredient matching the active medication in appearance. Other Name: Sugar pill Behavioral: Cognitive Behavioral Therapy (CBT) Participants (...) retardation or other severe cognitive impairment, prison or jail inmates, pregnant or nursing women, or women of childbearing age who will not use hormonal contraceptives, abstinence, or other acceptable methods of birth control during the study. Currently experiencing psychotic features (delusions, hallucinations, disorganized thought processes). Initiation of antidepressants, mood stabilizers, or psychotherapy within the past 14 days. High risk for suicide, defined as any suicide attempt in the past 6

2008 Clinical Trials

1340. Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder

, dysphoria, motor coordination, mental-cognitive functioning, eating habits, social impairment, sex drive, and physical symptoms. PMTS-O or PMTS-SR? Min=0 (asymptomatic), Max=40 (Highly symptomatic), higher scores indicate most severe problems Inventory of Depression Symptoms (IDS-C) [ Time Frame: Measured from baseline to Cycle 6 ] Inventory of Depressive Symptomatology-Clinician version (IDS-C) - a depression measure that has 28 items and detects appropriate variations between follicular and luteal (...) associated with PMDD. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that has been approved by the U.S. Food and Drug Administration (FDA) to treat PMDD. This study will evaluate the effectiveness of sertraline in reducing symptoms in women diagnosed with PMDD. All participants will begin this study by recording their symptoms for two complete menstrual cycles. At a baseline study visit, participants will then be randomly assigned to receive either sertraline or placebo for six menstrual

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>